Peptide Schedule
Amylin (IAPP)37 residuesKCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Amylin (IAPP)
Benefits
About Amylin (IAPP)
Amylin, also known as islet amyloid polypeptide (IAPP), is a 37-amino-acid peptide hormone produced by pancreatic beta cells and co-secreted with insulin in response to nutrient stimuli. Discovered in 1987 by Garth Cooper and colleagues from amyloid deposits in the pancreas of type 2 diabetics, amylin was quickly recognized as a physiologically important hormone with multiple roles in glucose homeostasis. In healthy individuals, amylin complements insulin through three distinct mechanisms: it slows gastric emptying via vagal signaling, suppresses postprandial glucagon secretion from pancreatic alpha cells, and promotes satiety through receptors in the area postrema and hypothalamus. These actions collectively flatten the postprandial glucose curve, reducing the demand on insulin. In type 1 diabetes, amylin production is lost entirely along with beta cells. In type 2 diabetes, amylin secretion is initially elevated but becomes progressively impaired as beta cells fail. The clinical challenge with native amylin is its strong propensity to misfold and aggregate into toxic amyloid fibrils. This amyloidogenesis is central to the pathology of type 2 diabetes — IAPP-derived amyloid deposits are found in the islets of over 90% of type 2 diabetes patients at autopsy and contribute to beta-cell death. The key amyloidogenic region spans residues 20-29, with residues S20-S29 forming a beta-sheet structure that nucleates fibril formation. Because native amylin cannot be used therapeutically due to aggregation, pramlintide was developed with three proline substitutions (A25P, S28P, S29P) that disrupt beta-sheet formation while preserving receptor activity. Pramlintide was FDA-approved in 2005 as adjunctive therapy for insulin-treated diabetes. The next-generation analog cagrilintide (developed by Novo Nordisk) uses acylation technology to extend the half-life to approximately one week, enabling weekly dosing and improved adherence. Native amylin remains an extensively studied research tool for understanding amyloid biology, neurodegenerative diseases (IAPP amyloid shares structural similarities with amyloid-beta in Alzheimer's), and metabolic signaling pathways. It is not used therapeutically.
Who Should Consider Amylin (IAPP)
- Researchers studying amyloid formation and protein misfolding diseases
- Scientists investigating pancreatic beta-cell biology and type 2 diabetes pathogenesis
- Research groups exploring amylin receptor pharmacology and metabolic signaling
- Neuroscience researchers studying parallels between IAPP and amyloid-beta aggregation
- Drug development teams using native IAPP as a reference compound for analog design
How Amylin (IAPP) Works
Amylin (IAPP) binds to amylin receptors, which are heterodimeric complexes formed by the calcitonin receptor (CTR) co-expressed with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). The combination of CTR with different RAMPs produces AMY1, AMY2, and AMY3 receptor subtypes with varying pharmacological profiles. Amylin also has cross-reactivity at calcitonin gene-related peptide (CGRP) receptors. Gastric emptying: Amylin activates receptors in the area postrema, a circumventricular organ outside the blood-brain barrier. This triggers vagal efferent signaling that inhibits gastric motility and slows pyloric emptying. The result is a more gradual delivery of nutrients to the small intestine and a flattened postprandial glucose curve. Glucagon suppression: Amylin acts on alpha cells (likely through paracrine signaling and central pathways) to suppress glucagon secretion specifically in the postprandial state. Importantly, this suppression is meal-specific — amylin does not impair the counter-regulatory glucagon response to hypoglycemia, preserving this critical safety mechanism. Satiety: Amylin receptors in the area postrema and nucleus of the solitary tract activate ascending pathways to the lateral parabrachial nucleus and hypothalamus, promoting meal termination and reducing food intake. This central satiety effect is additive with GLP-1 receptor activation, which is why amylin-GLP-1 combination approaches (e.g., cagrilintide + semaglutide) show enhanced weight loss. Amyloid formation: The 20-29 residue segment of human IAPP is intrinsically disordered in solution but can adopt beta-sheet conformation under conditions favoring aggregation (high concentration, low pH, membrane interaction). Monomers form oligomers, then protofibrils, then mature amyloid fibrils. The oligomeric intermediates are thought to be the most cytotoxic species, disrupting cell membranes through a pore-forming mechanism similar to antimicrobial peptides.
What to Expect
In research settings, subcutaneous amylin produces rapid physiological effects: gastric emptying slows within 15-30 minutes, postprandial glucagon is suppressed, and satiety signaling increases. Effects parallel those of pramlintide but with shorter duration due to the ~15-minute half-life. Nausea may occur at higher doses.
Repeated dosing in preclinical models shows consistent postprandial glucose reduction and food intake suppression. Aggregation at injection sites may occur with repeated subcutaneous administration — a limitation not seen with pramlintide.
In chronic preclinical studies, amylin-treated animals show reduced weight gain and improved glucose tolerance. However, local amyloid deposition at injection sites has been observed in some models, underscoring why native amylin was replaced by pramlintide for therapeutic use.
At 25-50 micromolar concentrations in neutral buffer, native amylin shows a characteristic sigmoidal aggregation curve: a lag phase of 2-8 hours (nucleation), a rapid growth phase of 4-12 hours (fibril elongation), and a plateau by 24-48 hours (mature fibrils). Thioflavin T fluorescence and electron microscopy are standard monitoring methods.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mcg | 3x Daily |
| Moderate | 25mcg | 3x Daily |
| Aggressive | 50mcg | 3x Daily |
Note: Research-only peptide. Native human amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. It plays a key physiological role in glucose homeostasis, but its tendency to aggregate into amyloid fibrils limits clinical use. The FDA-approved analog pramlintide (Symlin) has three proline substitutions that prevent aggregation. Cagrilintide is a next-generation long-acting amylin analog in late-stage development. Native amylin is used in research settings to study amyloid formation, beta-cell toxicity, and metabolic signaling.
How to Inject Amylin (IAPP)
Research use only. Native human amylin is typically reconstituted in sterile water or buffer at acidic pH (pH 3-4) to slow aggregation, then diluted to working concentration immediately before use. For in vitro amyloid studies, dissolve in hexafluoroisopropanol (HFIP), lyophilize aliquots, and reconstitute fresh in buffer. For subcutaneous research protocols, doses in the range of 10-50 mcg have been used in preclinical models, administered before meals to mimic physiological secretion patterns. The peptide solution must be freshly prepared — do not store reconstituted amylin for extended periods as aggregation begins within hours at neutral pH. For therapeutic amylin replacement, use the FDA-approved analog pramlintide instead.
Cycling Protocol
Not applicable — amylin (IAPP) is a research-only peptide without established clinical cycling protocols. For the therapeutic analog pramlintide, continuous daily dosing is used. For research applications, native amylin is typically used in acute experiments rather than chronic dosing schedules due to its aggregation tendency.
Pharmacokinetics
Source: Native human amylin has a plasma half-life of approximately 13-22 minutes (~15 min average) due to rapid renal clearance and enzymatic degradation by insulin-degrading enzyme (IDE) and neprilysin.
Loading the interactive decay curve.
Side Effects
Native amylin is not used clinically, so side effect data comes from research and extrapolation from the pramlintide analog. In preclinical models, native amylin at high concentrations is cytotoxic to beta cells due to amyloid fibril formation. Aggregated IAPP disrupts cell membranes, triggers ER stress, activates the NLRP3 inflammasome, and induces apoptosis. At physiological concentrations, soluble amylin produces nausea and reduced appetite via area postrema signaling (the same mechanism behind pramlintide's GI side effects). Hypoglycemia is possible when amylin is combined with insulin or insulin secretagogues. In research settings with subcutaneous administration, injection site reactions and transient nausea are the most commonly noted effects. The amyloidogenic potential of native amylin is the primary safety concern — aggregated fibrils are toxic to pancreatic islet cells and potentially to other tissues.
Contraindications
- Not intended for therapeutic use in humans — use pramlintide (Symlin) for clinical amylin replacement
- Patients with type 2 diabetes should not be exposed to native amylin due to amyloidogenic toxicity risk
- Individuals with gastroparesis or severe GI motility disorders — amylin further delays gastric emptying
- Known hypersensitivity to amylin or related peptides
- Pregnancy and breastfeeding — no safety data; not appropriate for non-research use
- Any clinical or self-administration setting — this is a research reagent, not a therapeutic product
Drug Interactions
- Insulin and insulin secretagogues — additive hypoglycemia risk when combined with amylin in research protocols
- GLP-1 receptor agonists (semaglutide, liraglutide) — overlapping gastric emptying and satiety effects; combined use studied in research contexts (amylin + GLP-1 complementary effects)
- Anticholinergic agents — additive delay in gastric emptying
- Oral medications — amylin slows gastric emptying and may alter absorption kinetics of co-administered oral compounds in research subjects
- Alpha-glucosidase inhibitors — both mechanisms delay carbohydrate processing; combined effects on GI motility may be excessive
Storage & Stability
Molecular Profile
Related Peptides
References
- Islet amyloid polypeptide: identification and characterization (Proc Natl Acad Sci 1987)PubMed 3299384
- Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus (Physiol Rev 2011)Review
- Amylin: pharmacology, physiology, and clinical potential (Pharmacol Rev 2015)Review
- Mechanisms of IAPP amyloidosis and beta-cell toxicity (Diabetes 2004)PubMed 14988259
- Amylin and calcitonin receptor pharmacology (Br J Pharmacol 2012)Review
- CagriSema (cagrilintide + semaglutide) for type 2 diabetes and obesity — Phase 3 clinical trialClinical Trial